Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

5

Dec 2025

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based Cellgorithm technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.

Most Americans still back early hepatitis B vaccination despite policy debate

5

Dec 2025

Most Americans still back early hepatitis B vaccination despite policy debate

On December 5, 2025, the Trump administration's Advisory Committee on Immunization Practices (ACIP), whose members were handpicked by Health and Human Services (HHS) Secretary and vaccination critic Robert F. Kennedy Jr., is scheduled to determine whether it should recommend that the Centers for Disease Control and Prevention (CDC) change the recommendation in place since 1991 that newborns be vaccinated against hepatitis B.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.